THERAPEUTIC AGENT FOR DRY EYE ASSOCIATED WITH SJOGREN'S SYNDROME

摘要

The present invention pertains to a pharmaceutical composition that contains ozagrel or a pharmacologically acceptable salt thereof as an active ingredient and that is for treating dry eye associated with Sjogren's syndrome. The pharmaceutical composition of the present invention has a strong tendency to persist even after administration of an eye drop of a general therapeutic agent (e.g., artificial tears, etc.) for dry eye, and exhibits particularly excellent therapeutic effect for treating disorders of the conjunctiva epithelium and the cornea related to dry eye associated with Sjogren's syndrome. Thus, the pharmaceutical composition of the present invention is useful as a pharmaceutical composition for treating dry eye associated with Sjogren's syndrome.